Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Clinical Trials 130

Clinical Trials Drugs Trials Therapies 130

Drug Discovery World

MAY 6, 2024

Even before this, however, Amsterdam was established as an important centre for drug development. The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function. The CDD will sponsor and manage KWF-supported trials.

Drugs 147

Drugs Molecular Biology Science Clinical Trials 147

Drug Discovery World

MAY 3, 2023

From the outset, our goal has been to streamline the cancer drug development process and our key opinion leaders are playing a vital role in helping us de-risk drug selection and advance high-quality assets quickly.” The post Scientific Affairs Group expands to over 200 oncologists appeared first on Drug Discovery World (DDW).

Drug Development 130

Drug Development International Therapies Drugs 130

FDA Law Blog: Drug Discovery

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” It finalized a draft guidance published in 2022.

Therapies 59

Therapies FDA Production Regulations 59

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

SEPTEMBER 12, 2022

If anything, this period has been a reminder that people are the primary reason we do what we do, and the Patient Access, Healthcare & People track at Advanced Therapies Europe 2022 allowed DDW’s Multimedia Editor Megan Thomas to share several reflections on the topic. .

Clinical Trials 130

Clinical Trials Trials Therapies Science 130

Drug Discovery World

JUNE 29, 2023

It’s been another busy month for senior appointments in the drug discovery sector. David Favre, Chief Development Officer, SpliceBio Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.

Drugs 130

Drugs Laboratories Research Laboratories Clinical Trials 130

Drug Discovery World

SEPTEMBER 7, 2023

However, despite the fact that children’s response to adult cancer drugs is often poor, due to the challenges of developing medicines for this population, only six drugs are made specifically for childhood cancer.

Clinical Trials 147

Clinical Trials Trials Drugs DNA 147

Drug Discovery World

FEBRUARY 3, 2023

Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will allow the development of a novel approach to treating tumours, and a new global commission will seek to improve access to personalised therapies.

FDA Approval 130

FDA Approval Drugs Therapies Treatment 130

Drug Discovery World

MARCH 13, 2024

In terms of drug discovery, every year the agency awards national grants through the Singapore Therapeutics Development Review (STDR), designed to boost the quality and quantity of drug development and biotech pipelines in Singapore 3. One area of weakness could be in translating innovative science into a viable business.

Government 173

Government Science Pharmaceuticals Vaccine 173

Drug Discovery World

JUNE 6, 2023

The international RAMP-201 study, led by researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK, and sponsored by Verastem Oncology, tested avutometinib alone and in combination with defactinib in 29 patients with LGSOC.

Drugs 130

Drugs Treatment Clinical Trials Trials 130

Drug Discovery World

FEBRUARY 13, 2023

DDW: What are some of the challenges in early-stage drug discovery and development? SB: The pursuit of safe and effective therapies is filled with challenges as evidenced by only about 10% or less of drug candidates successfully making it from discovery, through development and registration, and ultimately to patients.

RNA 130

RNA Drugs Immune Response Therapies 130

Drug Discovery World

FEBRUARY 10, 2023

Swedish life sciences industry organisation Lif put the success down to the government’s continued investment in life sciences and the increase in international companies investing in Sweden’s manufacturing sector. Indeed, for the first six months of 2022, medicines accounted for 7.1%

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

SEPTEMBER 14, 2023

Evaluating Immatics’ IMA203 TCR-T therapy, targeting PRAME, in combination with Moderna’s PRAME mRNA-based cancer vaccine.

Vaccine 130

Vaccine Bioinformatics Clinical Trials Therapies 130

PPD

MARCH 26, 2024

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Research Clinical Development Drug Development 98

Drug Discovery World

MARCH 6, 2023

In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors. The post Institiute gives a boost to five new life science start-ups appeared first on Drug Discovery World (DDW).

Science 130

Science RNA Disease International 130

The Pharma Data

NOVEMBER 9, 2020

. “Our initial focus is to develop standardized drug formulations with precise, predictable and efficient API delivery for clinical study and therapeutic use.” Psilocybin has recently been designated twice as a “breakthrough therapy” by the U.S. ” Prof.

Drug Development 40

Drug Development Drugs Clinical Pharmacology Pharmaceuticals 40

Drug Discovery World

JULY 5, 2023

Through such therapies, slowly, hesitatingly, some people are using the word ‘cure’ with a few individual cancer patients, which is something the field has avoided for decades. These types of therapies are often more effective and have fewer side effects. We’re starting to see that this goal is realisable.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

Conversations in Drug Development Trends

JANUARY 24, 2024

Why Partnering with Genetic Counselors May Benefit Your Clinical Program The American College of Medical Genetics (ACMG) has issued a statement that geneticists should be involved in the development of genetic therapies. As of July 2023, the American Society of Cell + Gene Therapy stated there were 3,905 therapies in development.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Discovery World

OCTOBER 20, 2022

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research. . Overview . Investment and collaboration . Start-up ecosystem .

International 130

International Drugs Science Government 130

Drug Target Review

JUNE 17, 2024

I am now incredibly privileged to work at the nexus of science and medicine in radiopharmaceutical drug development, and use my built-in scientific lens every day. This therapy is now widely used, but preparing radioactive chemicals to inject into patients many years ago when I was a fresh PhD candidate felt like a very big step.

Science 58

Science Therapies International Hospitals 58

Drug Discovery World

OCTOBER 6, 2022

With key players including AstraZeneca, Bayer, Novartis and Pfizer pushing the boundaries of drug development, the reason behind this growth is evident. In Germany the development of the Covid-19 vaccine, largely due to the achievements of BioNTech, raised the country’s biotech profile. billion, equivalent to $3.7

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

The Pharma Data

MARCH 22, 2021

Novartis is committed to reimagining prostate cancer through targeted radioligand therapy with 177 Lu-PSMA-617. More than 15 dedicated early to late development and research programs underway to identify the next wave of radioligand therapies for cancer. About 177 Lu-PSMA-617.

Therapies 52

Therapies Treatment Trials DNA 52

DrugBank

MAY 15, 2024

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Target Review

MAY 27, 2024

Caris Discovery, the therapeutic research arm of Caris Life Sciences, was launched to address the paucity of novel oncology drug targets and is uniquely poised to discover first-in-class ADC targets. What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans?

Clinical Trials 58

Clinical Trials Science Molecular Biology Bioinformatics 58

PPD

JUNE 7, 2023

The number of pediatric patients diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is on the rise, yet there are currently no approved therapies to treat NAFLD and NASH in adult or pediatric populations. As therapies for the treatment of NASH in adult patients go this year to the U.S.

Trials 98

Trials Clinical Trials Clinical Research Disease 98

H1 Blog

SEPTEMBER 26, 2023

Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. A recent McKinsey analysis of drugs and vaccines developed since 2000 shows that it takes nearly ten years to go from clinical testing to approval. First let’s look at some challenges and then opportunities.

Trials 59

Trials Clinical Trials International Regulations 59

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required.

Small Molecule 110

Small Molecule Therapies Treatment Immune Response 110

Drug Discovery World

JANUARY 31, 2023

But first, there is the urgency of getting the new drug application (NDA) or biologics license application (BLA) filing into the hands of the respective regulatory authorities. Over the last decade, many pharmaceutical companies have undertaken internal ‘harmonisation’ projects.

Production 246

Production Engineering Pharmaceutical Companies FDA 246

Drug Discovery World

AUGUST 31, 2022

A new study, published in the Annals of Internal Medicine , shows that higher levels of viral antigen in the blood, which could indicate ongoing SARS-CoV-2 replication, correlated with more severe disease. .

Hospitals 130

Hospitals Trials Virus International 130

The Pharma Data

DECEMBER 15, 2020

TOMI-T1D is an international partnership between academia, the pharmaceutical industry and nonprofit organizations. The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools.

Drug Development 40

Drug Development Clinical Trials Vaccine Trials 40

The Pharma Data

OCTOBER 9, 2021

Neumora leverages proprietary multimodal capabilities and technologies to integrate advanced computational data science with R&D to increase the probability of success of drug development in brain diseases. executive vice president of Research and Development at Amgen. Reese, M.D.,

Disease 40

Disease Therapies Science Drug Development 40

Drug Discovery World

AUGUST 5, 2022

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Why sponsors use external consultants.

Drug Development 130

Drug Development Drugs Pharma Companies International 130

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif.

Therapies 52

Therapies Production Government Biosimilars 52